Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399), a prominent pharmaceutical company based in China, has announced that it has received marketing approval from New Zealand’s Medicines and Medical Devices Safety Authority (MEDSAFE) for its enoxaparin sodium injection, which will be marketed under the trade name Exarane.
Enoxaparin sodium injection is a low molecular weight heparin (LMWH) used for a range of cardiovascular conditions. It is indicated for the treatment of acute ST segment elevation myocardial infarction (STEMI), including in patients who require medication or undergo subsequent percutaneous coronary intervention (PCI). The drug also plays a crucial role in preventing venous thromboembolism in patients bedridden due to acute conditions such as heart failure, respiratory failure, severe infections, and rheumatism. Furthermore, it is used for preventing venous thromboembolic diseases in orthopedic, general surgery, colorectal cancer, and cancer surgery patients, treating venous thromboembolic diseases, and in combination with aspirin, for treating unstable angina and non Q-wave myocardial infarction.
This approval marks a significant step for Hepalink as it expands its global footprint and offers a critical treatment option for cardiovascular health in New Zealand.- Flcube.com
